301 related articles for article (PubMed ID: 38474014)
41. The cGAS/STING/IFN-1 Response in Squamous Head and Neck Cancer Cells after Genotoxic Challenges and Abrogation of the ATR-Chk1 and Fanconi Anemia Axis.
Zahnreich S; El Guerzyfy S; Kaufmann J; Schmidberger H
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834346
[TBL] [Abstract][Full Text] [Related]
42. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury A; Hall S; Curtin N; Drew Y
Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
[TBL] [Abstract][Full Text] [Related]
43. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
Edwards TG; Bloom DC; Fisher C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
[TBL] [Abstract][Full Text] [Related]
44. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
45. Roles of ATM and ATR-mediated DNA damage responses during lytic BK polyomavirus infection.
Jiang M; Zhao L; Gamez M; Imperiale MJ
PLoS Pathog; 2012; 8(8):e1002898. PubMed ID: 22952448
[TBL] [Abstract][Full Text] [Related]
46. Distinct roles of ATR and DNA-PKcs in triggering DNA damage responses in ATM-deficient cells.
Tomimatsu N; Mukherjee B; Burma S
EMBO Rep; 2009 Jun; 10(6):629-35. PubMed ID: 19444312
[TBL] [Abstract][Full Text] [Related]
47. UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation requires replication stress.
Ward IM; Minn K; Chen J
J Biol Chem; 2004 Mar; 279(11):9677-80. PubMed ID: 14742437
[TBL] [Abstract][Full Text] [Related]
48. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Min A; Im SA; Jang H; Kim S; Lee M; Kim DK; Yang Y; Kim HJ; Lee KH; Kim JW; Kim TY; Oh DY; Brown J; Lau A; O'Connor MJ; Bang YJ
Mol Cancer Ther; 2017 Apr; 16(4):566-577. PubMed ID: 28138034
[TBL] [Abstract][Full Text] [Related]
49. Molecular Pathways: Targeting ATR in Cancer Therapy.
Karnitz LM; Zou L
Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
[TBL] [Abstract][Full Text] [Related]
50. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Mei L; Zhang J; He K; Zhang J
J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
[TBL] [Abstract][Full Text] [Related]
51. HUS1 regulates in vivo responses to genotoxic chemotherapies.
Balmus G; Lim PX; Oswald A; Hume KR; Cassano A; Pierre J; Hill A; Huang W; August A; Stokol T; Southard T; Weiss RS
Oncogene; 2016 Feb; 35(5):662-9. PubMed ID: 25915840
[TBL] [Abstract][Full Text] [Related]
52. Specific Human ATR and ATM Inhibitors Modulate Single Strand DNA Formation in
da Silva RB; Bertoldo WDR; Naves LL; de Vito FB; Damasceno JD; Tosi LRO; Machado CR; Pedrosa AL
Front Cell Infect Microbiol; 2021; 11():802613. PubMed ID: 35059327
[No Abstract] [Full Text] [Related]
53. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
54. Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.
Zhang S; Zhao Y; Wang X; Qi C; Tian J; Zou Z
Life Sci; 2023 Nov; 332():122131. PubMed ID: 37778414
[TBL] [Abstract][Full Text] [Related]
55. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
56. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.
Tibbetts RS; Cortez D; Brumbaugh KM; Scully R; Livingston D; Elledge SJ; Abraham RT
Genes Dev; 2000 Dec; 14(23):2989-3002. PubMed ID: 11114888
[TBL] [Abstract][Full Text] [Related]
57. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
[TBL] [Abstract][Full Text] [Related]
59. ATR- and ATM-Mediated DNA Damage Response Is Dependent on Excision Repair Assembly during G1 but Not in S Phase of Cell Cycle.
Ray A; Blevins C; Wani G; Wani AA
PLoS One; 2016; 11(7):e0159344. PubMed ID: 27442013
[TBL] [Abstract][Full Text] [Related]
60. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage.
Helt CE; Cliby WA; Keng PC; Bambara RA; O'Reilly MA
J Biol Chem; 2005 Jan; 280(2):1186-92. PubMed ID: 15533933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
